StreetInsider.com News Articles

University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program

Thu, 03 Sep 2026 07:56:00 -0400

University of Szeged installed Hungary’s first Robotic Magnetic Navigation system in July
Over 70 patients with all forms of arrhythmia treated robotically to date, a record pace of use globally
Robotics enabled successful treatment of patients with multiple previously failed ablation procedures
University of Szeged to celebrate leadership in technology and grand opening of Robotic Cardiology Program at upcoming scientific symposium on September 8th

ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the Electrophysiology team at

University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program

Thu, 03 Sep 2026 07:56:00 -0400

University of Szeged installed Hungary’s first Robotic Magnetic Navigation system in July
Over 70 patients with all forms of arrhythmia treated robotically to date, a record pace of use globally
Robotics enabled successful treatment of patients with multiple previously failed ablation procedures
University of Szeged to celebrate leadership in technology and grand opening of Robotic Cardiology Program at upcoming scientific symposium on September 8th

Stereotaxis (STXS) PT Lowered to $3 at Citizens on Top-Line Miss, Guidance Cut

Thu, 27 Aug 2026 04:12:18 -0400

Citizens analyst Daniel Stauder lowered the price target on Stereotaxis (NYSE: STXS) to $3.00 (from $4.00) while maintaining a Market Outperform rating.

The analyst commented, "We reiterate our Market Outperform rating and lower our price target to $3 from $4 on shares of Stereotaxis after updating our model to reflect 2Q26 operating results and FY26 updated guidance. Recall that 2Q26 results included a slight top-line miss relative to the Street (though revenue came in above our estimates) and that STXS lowered its guide for the remainder of the year on conservatism around system placements."

Stereotaxis (STXS) PT Lowered to $3 at Citizens on Top-Line Miss, Guidance Cut

Thu, 27 Aug 2026 04:12:18 -0400

Citizens analyst Daniel Stauder lowered the price target on Stereotaxis (NYSE: STXS) to $3.00 (from $4.00) while maintaining a Market Outperform rating.

Form SCHEDULE 13G Stereotaxis, Inc. Filed by: Kaufman Daniel Louis

Wed, 19 Aug 2026 17:41:00 -0400

si-local-file:///var/storage/secattach/20260819/26951311.html

Form SCHEDULE 13G Stereotaxis, Inc. Filed by: Kaufman Daniel Louis

Wed, 19 Aug 2026 17:41:00 -0400

si-local-file:///var/storage/secattach/20260819/26951311.html

Form EFFECT Stereotaxis, Inc.

Fri, 14 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26924084.html

Form EFFECT Stereotaxis, Inc.

Fri, 14 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26924084.html

Form EFFECT Stereotaxis, Inc.

Fri, 14 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26924086.html

Form EFFECT Stereotaxis, Inc.

Fri, 14 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26924086.html

Form 424B3 Stereotaxis, Inc.

Thu, 13 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26921375.html

Form 424B3 Stereotaxis, Inc.

Thu, 13 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26921375.html

Form 424B3 Stereotaxis, Inc.

Thu, 13 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260813/26921223.html

Form 424B3 Stereotaxis, Inc.

Thu, 13 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260813/26921223.html

Form 10-Q Stereotaxis, Inc. For: Jun 30

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26913003.html

Form 10-Q Stereotaxis, Inc. For: Jun 30

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26913003.html

Stereotaxis (STXS) PT Lowered to $3 at TD Cowen

Wed, 12 Aug 2026 09:44:10 -0400

TD Cowen analyst Joshua Jennings lowered the price target on Stereotaxis (NYSE: STXS) to $3.00 (from $5.00) while maintaining a rating.

Form 8-K Stereotaxis, Inc. For: Aug 11

Tue, 11 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260811/26905591.html

Form 8-K Stereotaxis, Inc. For: Aug 11

Tue, 11 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260811/26905591.html

Stereotaxis (STXS) Reports In-Line Q2 EPS

Tue, 11 Aug 2026 16:02:37 -0400

Stereotaxis (NYSE: STXS) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $7.67 million versus the consensus estimate of $8.68 million.

For earnings history and earnings-related data on Stereotaxis (STXS) click here.

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Tue, 11 Aug 2026 16:01:00 -0400

Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially
First GenesisX robotic system purchase by US hospital to be installed this fall
Multiple Synchrony digital operating room systems sold and installed following FDA clearance in April
Completed previously announced acquisition of Robocath, strengthening robotic technology leadership across the full spectrum of endovascular procedures

ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30,

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Tue, 11 Aug 2026 16:01:00 -0400

Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially
First GenesisX robotic system purchase by US hospital to be installed this fall
Multiple Synchrony digital operating room systems sold and installed following FDA clearance in April
Completed previously announced acquisition of Robocath, strengthening robotic technology leadership across the full spectrum of endovascular procedures

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Tue, 11 Aug 2026 16:01:00 -0400

Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially
First GenesisX robotic system purchase by US hospital to be installed this fall
Multiple Synchrony digital operating room systems sold and installed following FDA clearance in April
Completed previously announced acquisition of Robocath, strengthening robotic technology leadership across the full spectrum of endovascular procedures

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Tue, 11 Aug 2026 16:01:00 -0400

Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially
First GenesisX robotic system purchase by US hospital to be installed this fall
Multiple Synchrony digital operating room systems sold and installed following FDA clearance in April
Completed previously announced acquisition of Robocath, strengthening robotic technology leadership across the full spectrum of endovascular procedures

Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026

Tue, 21 Jul 2026 09:00:00 -0400

ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.

What:

Stereotaxis second